# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.05 ...
No Shareholder Action Required at This TimeWASHINGTON, May 7, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" ...
ShareCap calls on the Board to initiate a strategic alternatives process that, among the alternatives, reconsiders Future Pak...
"Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Le...
https://finance.yahoo.com/news/1-u-supreme-court-rejects-153720025.htmlThe U.S. Supreme Court on Monday declined to hear a bid ...
https://ml.globenewswire.com/Resource/Download/9ee5bd01-bdbc-43f7-af2d-e4c34004b336Dear Members of the Board: A fund managed by...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The D...